Глава 6. Себорейный дерматит

Gupta A.K., Versteeg S.G. Topical treatment of facial seborrheic dermatitis: a systematic review // Am. J. Clin. Dermatol. 2017. Vol. 18. N. 2. P. 193–213. DOI: https://doi.org/10.1007/s40257-016-0232-2. Epub 2016 Nov 02. PMID: 27804089.

Hald M., Arendrup M.C., Svejgaard E.L. et al. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases // Acta Derm. Venereol. 2015. Vol. 95. N. 1. P. 12–19. DOI: https://doi.org/10.2340/00015555-1825. PMID: 24556907.

Howard R. Leiner’s syndrome: erythroderma, diarrhea, and failure to thrive // Curr. Probl. Dermatol. 2000. Vol. 12. Issue 4. P. 183–185.

Kastarinen H., Oksanen T., Okokon E.O. et al. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp // Cochrane Database Syst. Rev. 2014. Issue 5. DOI: https://doi.org/10.1002/14651858.CD009446.pub2. PMID: 24838779; PMCID: PMC6483543.

Kibar M., Aktan Ş., Bilgin M. Dermoscopic findings in scalp psoriasis and seborrheic dermatitis; two new signs; signet ring vessel and hidden hair // Indian J. Dermatol. 2015. Vol. 60. N. 1. P. 41–45. DOI: https://doi.org/10.4103/0019-5154.147786. PMID: 25657395; PMCID: PMC4318061.

Kim G.-W., Jung H.-J., Ko H.-C. et al. Dermoscopy can be useful in differentiating scalp psoriasis from seborrheic dermatitis // Br. J. Dermatol. 2011. Vol. 164. N. 3. P. 652–656. DOI: https://doi.org/10.1111/j.1365-2133.2010.10180.x. Epub 2011 Feb 17. PMID: 21155753.

Kim T.-W., Mun J.-H., Jwa S.-W. et al. Proactive treatment of adult facial seborrheic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-center trial // Acta Derm. Venereol. 2013. Vol. 93. N. 5. P. 557–561. DOI: https://doi.org/10.2340/00015555-1532. PMID: 23388687.

Manriquez J.J., Uribe P. Seborrhoeic dermatitis // BMJ Clin. Evid. 2007. 2007; 1713. PMID: 19454093; PMCID: PMC2943817.

Medansky R., Lepaw M., Shavin J. et al. Mometasone furoate cream 0.1% vs. hydrocortisone cream 1% in the treatment of seborrhoeic dermatitis // J. Dermatolog. Treat. 1992. Vol. 3. N. 3. P. 125–128. DOI: https://doi.org/10.3109/09546639209088705.

Milani M., Di Molfetta S.A., Gramazio R. et al. Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients // Curr. Med. Res. Opin. 2003. Vol. 19. N. 4. P. 342–345. DOI: https://doi.org/10.1185/030079903125001875. PMID: 12841928.

Nobles T., Krishnamurthy K. Cradle Cap // StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2024 Jan. 2023 Aug 7. https://pubmed.ncbi.nlm.nih.gov/30285358/.

Nolting S., Hagemeier H.H. [Therapy of erythrosquamous dermatoses. Betamethasone dipropionate plus salicylic acid in comparison with betamethasone dipropionate solution] // Fortschr. Med. 1983. Vol. 101. N. 37. P. 1679–1683. PMID: 6227542. (In German).

Okokon E.O., Verbeek J.H., Ruotsalainen J.H. et al. Topical antifungals for seborrhoeic dermatitis // Cochrane Database Syst. Rev. 2015. Issue 4. DOI: https://doi.org/10.1002/14651858.CD008138.pub3. PMID: 25933684; PMCID: PMC4448221.

Opdyke D.L., Burnett C.M., Brauer E.W. Anti-seborrhoeic qualities of zinc pyrithione in a cream vehicle. II. Safety evaluation // Food Cosmet. Toxicol. 1967. Vol. 5. N. 3. P. 321–326. DOI: https://doi.org/10.1016/s0015-6264(67)83057-8. PMID: 4228290.

Ortonne J.-P., Nikkels A.F., Reich K. et al. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study // Br. J. Dermatol. 2011. Vol. 165. N. 1. P. 171–176. DOI: https://doi.org/10.1111/j.1365-2133.2011.10269.x. MID: 21707573.

Papp K.A., Papp A., Dahmer B., Clark C.S. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults // J. Am. Acad. Dermatol. 2012. Vol. 67. N. (1). P. e11–e15. DOI: https://doi.org/10.1016/j.jaad.2011.02.032. Epub 2011 Nov 21. PMID: 22101215.

Park J.-H., Park Y.J., Kim S.K. et al. Histopathological differential diagnosis of psoriasis and seborrheic dermatitis of the scalp // Ann. Dermatol. 2016. Vol. 28. N. 4. P. 427–432. DOI: https://doi.org/10.5021/ad.2016.28.4.427. PMID: 27489423; PMCID: PMC4969470.

Piérard-Franchimont C., Goffin V., Decroix J., Piérard G.E. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis // Skin Pharmacol. Appl. Skin Physiol. 2002. Vol. 15. N. 6. P. 434–441. DOI: https://doi.org/10.1159/000066452. PMID: 12476017.

Pirkhammer D., Seeber A., Hönigsmann H., Tanew A. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis // Br. J. Dermatol. 2000. Vol. 143. N. 5. P. 964–968. DOI: https://doi.org/10.1046/j.1365-2133.2000.03828.x. PMID: 11069503.

Ratnavel R.C., Squire R.A., Boorman G.C. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis // J. Dermatolog. Treat. 2007. Vol. 18. N. 2. P. 88–96. DOI: https://doi.org/10.1080/16537150601092944. PMID: 17520465.

Rigopoulos D., Ioannides D., Kalogeromitros D. et al. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial // Br. J. Dermatol. 2004. Vol. 151. N. 5. P. 1071–1075. DOI: https://doi.org/10.1111/j.1365-2133.2004.06208.x. PMID: 15541087.

Sampaio A.L., Mameri A.C., Vargas T.J. et al. Seborrheic dermatitis // An. Bras. Dermatol. 2011. Vol. 86. N. 6. P. 1061–1071. DOI: https://doi.org/10.1590/s0365-05962011000600002. PMID: 22281892.

Sauer G.C., Hall J.C. Manual of Skin Diseases. 7th ed. Lippincott Williams & Wilkins, 1996. 436 p.

Scaparro E., Quadri G., Virno G. et al. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil®) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial // Br. J. Dermatol. 2001. Vol. 144. N. 4. P. 854–857. DOI: https://doi.org/10.1046/j.1365-2133.2001.04144.x. PMID: 11298548.

Schwartz J.R., Messenger A.G., Tosti A. et al. A comprehensive pathophysiology of dandruff and seborrheic dermatitis — towards a more precise definition of scalp health // Acta Derm. Venereol. 2013. Vol. 93. N. 2. P. 131–137. DOI: https://doi.org/10.2340/00015555-1382. PMID: 22875203.

Schwartz R.A., Janusz C.A., Janniger C.K. Seborrheic dermatitis: an overview // Am. Fam. Physician. 2006. Vol. 74. N. 1. P. 125–130. PMID: 16848386.

Squire R.A., Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis // J. Dermatolog. Treat. 2002. Vol. 13. N. 2. P. 51–60. DOI: https://doi.org/10.1080/095466302317584395. PMID: 12060502.

Taieb A., Legrain V., Palmier C. et al. Topical ketoconazole for infantile seborrhoeic dermatitis // Dermatologica. 1990. Vol. 181. N. 1. P. 26–32. DOI: https://doi.org/10.1159/000247855. PMID: 2144249.

Unholzer A., Schinzel S., Nietsch K.-H. et al. Ciclopiroxolamine cream 1% in the treatment of seborrhoeic dermatitis: a double-blind, parallel-group comparison with ketoconazole and vehicle in a confirmatory trial // Clin. Drug. Invest. 2002. Vol. 22. N. 3. P. 167–172. DOI: https://doi.org/10.2165/00044011-200222030-00003. Epub 2012 Aug 24.

Victoire A., Magin P., Coughlan J., van Driel M.L. Interventions for infantile seborrhoeic dermatitis (including cradle cap) // Cochrane Database Syst. Rev. 2019. Issue 3. DOI: https://doi.org/10.1002/14651858.CD011380.pub2.

Wannanukul S., Chiabunkana J. Comparative study of 2% ketoconazole cream and 1% hydrocortisone cream in the treatment of infantile seborrheic dermatitis // J. Med. Assoc. Thai. 2004. Vol. 87. Suppl. 2. P. S68–S71. PMID: 16083165.

Warshaw E.M., Wohlhuter R.J., Liu A. et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis // J. Am. Acad. Dermatol. 2007. Vol. 57. N. 2. P. 257–264. DOI: https://doi.org/10.1016/j.jaad.2006.11.007. PMID: 17188780.